Reduction-responsive crosslinked micellar nanoassemblies for tumor-targeted drug delivery

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Drug Delivery

Background:

• Developing effective drug delivery systems is crucial for cancer therapy.
• Hydrophobic anticancer drugs often face challenges with solubility and targeted delivery.
• Nanoassemblies offer potential for improved pharmacokinetics and tumor targeting.

Purpose of the Study:

• To design and evaluate novel crosslinked nanoassemblies for enhanced drug delivery to tumors.
• To create a stable nanocarrier system capable of controlled drug release.
• To assess the therapeutic potential of these nanoassemblies in a preclinical cancer model.

Main Methods:

• Synthesis of a novel copolymer: polyethylene glycol 5000 (PEG114), Vitamin E (VE), and thioctic acid (TA) at a 1:4:4 molar ratio (PEG114-VE4-TA4).
• Self-assembly of the copolymer into micelles and subsequent formation of polydisulfide crosslinks.
• Characterization of physicochemical and biological properties of paclitaxel-loaded crosslinked micelles.
• Evaluation of pharmacokinetics and anticancer efficacy in a human ovarian cancer xenograft murine model.

Main Results:

• Crosslinked PEG114-VE4-TA4 micelles exhibited enhanced thermodynamic and kinetic stability.
• Disulfide crosslinks were glutathione-responsive, enabling accelerated drug release intracellularly.
• Paclitaxel-loaded crosslinked micelles achieved significantly higher plasma concentrations and tumor accumulation compared to non-crosslinked micelles and Taxol®.
• Superior tumor growth repression was observed with the paclitaxel-loaded crosslinked micelles.

Conclusions:

• The crosslinked PEG114-VE4-TA4 nanocarrier system demonstrates significant potential for delivering hydrophobic anticancer drugs.
• This platform offers improved stability, targeted release, and enhanced therapeutic efficacy.
• Further development could lead to more effective cancer treatment strategies.